US 12,440,499 B2
Topical composition
Nigel Crutchley, Guildford (GB); Michelle Georgiou, Guildford (GB); Stephen Lenon, Guildford (GB); and Morten Praestegaard, Guildford (GB)
Assigned to MC2 Therapeutics Limited, Guildford (GB)
Filed by MC2 Therapeutics Limited, Guildford (GB)
Filed on Mar. 20, 2023, as Appl. No. 18/123,828.
Application 18/123,828 is a continuation of application No. 16/982,281, granted, now 11,696,919, previously published as PCT/EP2019/056735, filed on Mar. 18, 2019.
Claims priority of application No. 18162664 (EP), filed on Mar. 19, 2018.
Prior Publication US 2023/0226077 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4709 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/047 (2006.01); A61K 31/085 (2006.01); A61K 31/355 (2006.01); A61K 31/573 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/44 (2017.01); A61P 17/00 (2006.01); A61P 17/04 (2006.01); A61P 17/10 (2006.01); A61P 31/04 (2006.01)
CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 31/047 (2013.01); A61K 31/085 (2013.01); A61K 31/355 (2013.01); A61K 47/44 (2013.01)] 11 Claims
 
1. A composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,
wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole,
wherein said at least one discontinuous oil phase comprises caprylic capric triglycerides and isopropyl myristate, wherein the isopropyl myristate and caprylic capric triglycerides are present in a weight ratio of from 4:1 to 8:1, and
wherein the composition has a pH of 7.75±0.5.